Grant: Discovery Grants Program - Individual
University of Guelph
$36,000.00
Synthesis of oligosaccharides and glycoconjugates to develop anti-cancer vaccines
EF 2019-20
Résumé
The basic expertise of our research group resides in synthetic carbohydrate chemistry. The main goal of research program is to design through chemical synthesis safe anti-cancer vaccines based on Tumor Associated Carbohydrates Antigens (TACAs). Our research program targets the antigens: dimericLex, LeaLex, Ley, LebLea and LeyLex (KH-1). We aim at discovering fragments of dimericLex and LeaLex that are able to trigger safe immune responses targeted against colorectal cancer cells and squamous lung carcinoma cells, respectively. We also aim at increasing the ability of the TACAs to trigger an efficient (T-cell dependent) immune response by investigating a new class of molecules made of the Ley antigen linked to a zwitterionic polysaccharide (PS A1). PS A1 is extracted from Bacteroides fragilis and has been shown to elicit the desired immune response without the need for an adjuvant or carrier protein. Given our expertise, we are also designing efficient synthetic strategies to prepare the more challenging heptasaccharides: LebLea and LeyLex (KH-1) which are both associated with adenocarcinomas. Because it has been well-established that cancer cells express several different TACAs at levels that vary over the course of cellular development, we will use these two antigens to investigate the preparation of divalent tetanus toxoid conjugates via amide bond formation and copper-free click chemistry. **
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2016-03820
Name nom
Auzanneau, FranceIsabelle
Department département
Chemistry
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2016
Award amount
36000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3702
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Carbohydrates
Research subject fr
Glucides
Installment
inst:4 - 5
Partie
4
Nb partie
5
Application title
Synthesis of oligosaccharides and glycoconjugates to develop anti-cancer vaccines
Keyword
NSERC
Application summary
The basic expertise of our research group resides in synthetic carbohydrate chemistry. The main goal of research program is to design through chemical synthesis safe anti-cancer vaccines based on Tumor Associated Carbohydrates Antigens (TACAs). Our research program targets the antigens: dimericLex, LeaLex, Ley, LebLea and LeyLex (KH-1). We aim at discovering fragments of dimericLex and LeaLex that are able to trigger safe immune responses targeted against colorectal cancer cells and squamous lung carcinoma cells, respectively. We also aim at increasing the ability of the TACAs to trigger an efficient (T-cell dependent) immune response by investigating a new class of molecules made of the Ley antigen linked to a zwitterionic polysaccharide (PS A1). PS A1 is extracted from Bacteroides fragilis and has been shown to elicit the desired immune response without the need for an adjuvant or carrier protein. Given our expertise, we are also designing efficient synthetic strategies to prepare the more challenging heptasaccharides: LebLea and LeyLex (KH-1) which are both associated with adenocarcinomas. Because it has been well-established that cancer cells express several different TACAs at levels that vary over the course of cellular development, we will use these two antigens to investigate the preparation of divalent tetanus toxoid conjugates via amide bond formation and copper-free click chemistry. **